Clinical Trial: Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07036016) titled 'Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1' on June 17.

Brief Summary: Importance:

EGFR tyrosine kinase inhibitors (EGFR-TKIs) and PD-1/PD-L1 immune checkpoint inhibitors are widely used in the treatment of non-small cell lung cancer (NSCLC). However, the safety profile of their combination-particularly the risk of interstitial pneumonitis (IP)-remains unclear.

Objective:

To evaluate the incidence and risk of interstitial pneumonitis associated with EGFR-TKIs when combined with PD-1/PD-L1 inhibitors, using real-world pharmacovigilance data.

Design, Setting, and Participants:

This retrospectiv...